Janel Corporation filings document material events, governance votes, financing arrangements and corporate-structure disclosures for the Nevada operating company. Form 8-K reports cover the completed transfer of Janel Group LLC membership interests to Rubicon Technology, Janel’s resulting ownership position in Rubicon, and senior secured credit facilities involving Janel Group and other subsidiaries.
Proxy and meeting filings describe director elections, advisory executive-compensation votes and the frequency of future say-on-pay votes. Other regulatory disclosures cover changes in the company’s independent registered public accounting firm, capital-structure matters, subsidiary obligations and segment references to Logistics, Life Sciences and Manufacturing operations.
Janel Corporation (JANL), through its wholly owned subsidiary Antibodies Incorporated, acquired 100% of EnCor Biotechnology Inc.’s issued and outstanding common shares on October 20, 2026. Consideration included $11,960,000 in closing cash and a subordinated promissory note with $5,040,000 principal. Janel said the acquisition was funded with cash provided by operations, borrowings under its Senior Credit Facility, and the note.
The Borrowers exercised a $15,000,000 increase in acquisition facility commitments; lenders immediately funded $11,000,000, which was used as cash consideration for the acquisition. The amendment also added an excess cash flow mandatory prepayment provision, waived restrictions and consented to the acquisition, and joined EnCor as a borrower contemporaneously with the acquisition. The SEC is considering Janel’s request for relief from EnCor’s historical audited and corresponding pro forma financial statements. To the extent those statements are required, Janel will file them by amendment as soon as practicable.
Janel Corp director Ryan Karen Miller received a direct award of 2,500 stock options to buy 2,500 shares of common stock on October 1, 2026. The options carry a $48-per-share exercise price, list December 31, 2028, as the exercise date, and expire September 30, 2036. The reported post-transaction position was 2,500 options.
Janel Corp director John Joseph Gonzalez II received a direct grant of 2,500 stock options on October 1, 2026. The options have an exercise price of $48 per share, an exercise date of December 31, 2028, and an expiration date of September 30, 2036. His reported resulting position was 2,500 options.
Janel Corp director Gerard van Kesteren received a grant of 2,500 stock options on October 1, 2026, covering 2,500 shares of Common Stock. The options have a $48 exercise price, an exercise date of December 31, 2028, and an expiration date of September 30, 2036. His reported position after the grant is 2,500 options.
Janel Corp (JANL) director Gregory J. Melsen received a direct grant of 2,500 stock options on October 1, 2026, covering 2,500 shares of Common Stock. The options have a $48 exercise price, an exercise date of December 31, 2028, and an expiration date of September 30, 2036. His reported post-transaction option position is 2,500.
Janel Corp director Gregory B. Graves received a grant of 2,500 stock options to acquire common stock on October 1, 2026. The options have a $48 exercise price, are exercisable on December 31, 2028, and expire September 30, 2036. The reported post-grant direct position was 2,500 options; this was an option award rather than a purchase of common shares.
JANEL CORP (JANL) director Gregory B. Graves reported two open-market purchases of the company’s Common Stock. He bought 300 shares at $50.00 per share on September 14, 2026, and 95 shares at $48.00 per share on September 11, 2026, for a total of 395 shares acquired. No Rule 10b5-1 trading plan is reported for these transactions.
JANEL CORP (JANL) director Gregory B. Graves purchased 400 shares of the company’s Common Stock on September 9, 2026 at $50.00 per share in an open-market or private transaction. Following this trade, he directly holds 7,507 shares of JANEL CORP common stock, and no Rule 10b5-1 plan is reported.
Janel Corporation reported higher results for the quarter ended June 30, 2026. Total revenues were $67,512, up from $49,145 a year earlier, driven mainly by Logistics, which generated $61,081. Net income attributable to Janel was $2,097, and net income available to common stockholders was $1,983, or diluted EPS of $1.63 versus $0.67.
For the nine-month period, revenues reached $180,995 compared with $151,230 in 2025. Net income attributable to Janel was $3,233, and net income available to common stockholders was $2,907, or diluted EPS of $2.39. Operating cash flow was $20,134, supporting cash and cash equivalents of $33,697 as of June 30, 2026.
Total assets were $192,000, including goodwill of $31,592 and intangible assets of $37,374. The company completed several transactions, including consolidating Rubicon in the Manufacturing segment and acquiring an antibody product line and related royalty stream, and now operates under a new $59,120 credit facility with $13,929 drawn on the asset-based revolver and $9,668 on the acquisition revolver while remaining in covenant compliance.
Janel Corp director Gregory B. Graves bought shares of the company in the open market. On this Form 4, he reported purchasing 225 shares of Janel Corp common stock at a price of $42.00 per share. After this transaction, he directly owns 7,107 shares of common stock. This is a relatively small, routine open-market purchase that modestly increases his personal stake in the company.